Nitric Oxide Releasing Solution to Treat and Prevent Exacerbation of Mild COVID-19 Infection

Phase 2

Withdrawn

• Conditions: SARS-CoV Infection
• Interventions: Drug: Nitric Oxide-Releasing Drug

• Registration Number: NCT04443868
• Lead Sponsor: Sanotize Research and Development corp.

Brief Summary

This is a double-blinded, placebo-controlled parallel, phase II clinical efficacy study evaluating Nitric Oxide Nasal Irrigation (NONI) for the treatment of COVID-19 in individuals with mild COVID-19 Infection.

Detailed Description

Up to 50 subjects will be enrolled into one of two cohorts of this study in a ratio of 1:1 (Treatment: Placebo Control). Subjects will be screened and randomized into one of two parallel cohorts.

* Treatment (N = up to 25): Subjects will be enrolled and receive daily NONI treatment for 14 days with a follow-up visit on Day 28 post randomization.

* Placebo (N = up to 25): Subjects will be enrolled and receive a placebo for 14 days with a follow-up visit on Day 28 post randomization.

Study Timeline

• Study First Submitted: 2020-06-20
• Study First Submitted QC: 2020-06-20
• Study First Posted: 2020-06-23
• Study Start: 2021-01
• Primary Completion: 2021-04
• Status Verified: 2021-07
• Study Completion: 2021-07
• Last Update Submitted: 2021-07-12
• Last Update Posted: 2021-07-16

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Capable of understanding and providing signed informed consent and ability to adhere to the requirements and restrictions of this protocol;

• Men and Women ≥ 18years of age;

• Internet access and capability and willingness to use to participate in audio or audio/video engagements with medical professionals, receive texts, emails, and phone calls from study staff and have a device and reasonable cellular data or other internet access to submit daily study required information using a smart phone, tablet, laptop, or desktop computer during the study period;

• COVID-19 infection confirmed with a laboratory antigen or SARS-CoV-2 RT-PCR nasal swab;

• Specimen collected within the past 48 hours;

• Mild COVID /FLU symptoms which may include no symptoms, fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal symptoms, lack of taste or smell without shortness of breath or dyspnea;

• Must be willing to use one highly effective birth control method which include: abstinence, hormonal contraceptives (e.g. combined oral contraceptives, patch, vaginal ring, injectables, and implants); intrauterine device (IUD) or intrauterine system (IUS); vasectomy and tubal ligation or to use two forms of effective birth control methods which include: barrier methods of contraception (e.g. male condom, female condom, cervical cap, diaphragm, contraceptive sponge);

  • Hormonal methods and the IUD must be in use at least 30 days prior to first Study drug administration
  • Abstinence and barrier methods must be in use at least 14 days prior to Study drug administration
  • Vasectomy must be completed 3 months prior to first Study drug administration; or in the alternative that a 0 sperm count will suffice.

Exclusion Criteria

• Current tracheostomy or laryngectomy;
• Concomitant respiratory therapy such as oxygen or ventilatory support. Positive airway pressure for obstructive sleep apnea is permitted if treatment was established with good compliance at least 3 months before enrolment;
• Need for hospitalization for any reason;
• Inability to safely self-administer nasal irrigation
• Any clinical contraindications, as judged by the Qualified Medical Practitioner;
• Clinical signs indicative of moderate, severe or critical COVID severity symptoms (as defined by FDA COVID-19 Guidance Document)
• Mentally or neurologically disabled patients who are considered not fit to consent to their participation in the study;
• Lactating, pregnant or planning to become pregnant during the study period;
• Diagnosed with prior COVID-19 infection (>48 hours from the time the test is reported prior to the time of screening).

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Nitric Oxide Releasing Solution	Nitric Oxide-Releasing Drug	Daily nasal irrigation (240mL) 14.4ppm
Placebo Isotonic Saline	Nitric Oxide-Releasing Drug	Daily nasal irrigation (240mL) 0.9% saline

Primary Outcome Measures

Name	Time	Method
To Measure the efficacy of NONI compared to saline placebo control to shorten the duration of COVID-19 viral infectivity	6 Days	Measure the SARS-CoV-2 viral load (Cycle threshold) at baseline through Day 6 between NONI and control arms.

Secondary Outcome Measures

Name	Time	Method
To measure the tolerance of NONI compared to saline placebo in participants with mild COVID-19 infection	14 days	Severity and frequency of adverse events, pain, discomfort or discontinuations of treatment.
To Measure the virucidal effect of NONI compared to placebo in the nasal cavity in subjects with mild COVID-19 infection	2, 4 and 6 days	Measure the difference in time-to Ct threshold (ie: unmeasurable viral load) between NONI and control.
To Measure the efficacy of NONI in prevention of progression of COVID-19	28 days	Measure the proportion of subjects requiring hospitalization or ER/ED visits for COVID-19/flu-like symptoms
To measure reduction of patient reported outcome (PRO) of clinical cold score symptoms and quality of life (QoL) in subjects with COVID-19	6 days	Measure the difference in 12-point COVID Symptom PROs score 0-3 (min 0 \& max 36) and a QoL score from 0-100 (lower is worse) from baseline between NONI and control arms.
To measure reduction of patient reported outcome (PRO) of clinical cold score symptoms and quality of life in subjects with COVID-19	2, 4, 6, 14 and 28 days	Measure the difference in proportion of subjects with reduction to a score of zero from baseline between NONI and control arms.